NASDAQ, AMGN - Amgen Inc
Amgen Inc. (including its subsidiaries, referred to as ?Amgen,? ?the Company,?
?we,? ?our? and ?us?) was incorporated in 1980 and is a global biotechnology
company that discovers, develops, manufactures and markets human therapeutics
based on advances in cellular and molecular biology. We operate in one business
segment ? human therapeutics.
We market human therapeutic products in the areas of supportive cancer care,
nephrology, inflammation and oncology. Our principal products include Aranesp?
(darbepoetin alfa), EPOGEN ? (Epoetin alfa), Neulasta? (pegfilgrastim),
NEUPOGEN? (Filgrastim) and Enbrel ? (etanercept). Aranesp? and EPOGEN? stimulate
the production of red blood cells to treat anemia and belong to a class of drugs
referred to as erythropoiesis-stimulating agents (?ESAs?). Aranesp? is used for
the treatment of anemia both in supportive cancer care and in nephrology.
EPOGEN? is used to treat anemia associated with chronic renal failure (?CRF?). ...
Read SEC Filing on NASDAQ.com »